4.2.4.3.2.3. urethral bulking agents. concept procedure originates idea intra- peri-urethral injection agent able form artificial cushions under/around urethra increases resistance bladder outlet facilitates continence. cochrane sr , 2,004 patients included fourteen trials seven different types intraurethral injection: ethylene vinyl alcohol copolymer (uryx™), glutaraldehyde cross-linked collagen (contigent©), porcine dermal implant (permacol©), solid silicone elastomer (macroplastique©), autologous fat, pyrolytic carbon (durasphere©), calcium hydroxylapatite (coaptite©), polytetrafluoroethylene (polytef™) hyaluronic dextran polymer (zuidex©). conclusions state available evidence base remains insufficient guide practice . recent sr 56 studies conclude available data support use bulkamid® macroplastique®, shown short-term efficacy 30%–90% 40%–85%, respectively, long-term efficacy 42%–70%, 21%–80%, respectively. bulkamid® appears favourable safety profile, cases erosion migration product associated use. direct comparisons urethral bulking agents performed . sr 23 studies using macroplastique© including 958 patients showed 75% improvement 43% dry rate < 6 months 64% improvement 36% cure rate > 18 months . review 514 elderly women sui treated various agents showed reduced pad weight 73% one-year follow-up, independent material injected . heterogeneity populations, variety materials used lack long-term follow-up limit guidance practice. studies showed tendency short-term improvement ui, exception one rct, find difference saline fat injection . one trial 30 women showed weak, non-significant advantage terms patient satisfaction mid-urethral injection comparison bladder neck injection demonstrable difference continence levels . one small trial found 30% (six 20) patients developed retention urine following peri-urethral injection compared 5% (one 20) transurethral injection . small rct found difference efficacy mid-urethral bladder neck injection collagen . one study treated patients received radiotherapy injection bulkamid® reported ~25% cure short-term follow-up . bulking agent injection generally safe, frequent adverse event uti. however, autologous fat hyaluronic acid used due risk fatal embolism local abscess formation, respectively . study reported women treated high-volume surgeon (defined > 75 urethral bulking injections performed surgical career) increased chance cure lower risk hospital contact postoperatively, compared women treated low-volume surgeon. risk 30-day hospital contact also lower women treated high-volume department (defined > 15 procedures performed per year) . comparison surgical procedures two rcts compared collagen injection conventional surgery sui (silicon particles vs. autologous sling collagen vs. surgical procedures). studies reported greater efficacy higher complication rates open surgery . recent non-inferiority clinical trial, women primary sui randomised tvt polyacrylamide hydrogel urethral bulking agent injection (bulkamid®) . mid-urethral tvt slings associated better satisfaction cure rates bulkamid® primary sui. objective cure rate, cough stress test negative 95.0% patients underwent tvt vs. 66.4% underwent bulkamid®. another sr examining relative efficacy urethral bulking agents included six studies quantitative synthesis total 710 patients. authors found bulking agents less effective surgical procedures according subjective improvement treatment (relative risk [rr] = 0.70; 95% ci: 0.53-0.92). however, main limitation sr meta-analysis absence common objective outcome measure evaluate effectiveness. 4.2.4.3.2.3.1.summary evidence recommendations urethral bulking agents summary evidenceleurethral bulking agents may provide short-term improvement cure women sui.1bbulking agents less effective mus, burch colposuspension autologous sling cure sui repeat injections may required order achieve sustained benefits.1bautologous fat hyaluronic acid bulking agents higher risk adverse events.1aadverse event rates urethral bulking agents lower compared open surgery.2athere evidence one type bulking agent better another.1bthe peri-urethral route injection bulking agents may associated higher risk urinary retention compared transurethral route.2b recommendationsstrength ratingoffer urethral bulking agents women seeking surgical treatment stress urinary incontinence (sui) following thorough discussion risks benefits relative surgical modalities.strongoffer urethral bulking agents women sui request low-risk procedure understanding efficacy lower surgical procedures, repeat injections likely, long-term durability safety established.strongdo offer autologous fat hyaluronic acid urethral bulking agents due higher risk adverse events.strong